The Role of IDH Inhibitors in Hematologic Malignancies
AML What Is It and How Did It Get There?
Key Points From De Novo AML Genome Atlas-1
AML A Long List of Prognostic Features
Selected Targeted Therapy in AML
The Evolution of the Discovery of IDH Mutations in Cancer by Year
IDH Mutations Also Found in MDS, NHL and Range of Solid Tumors
IDH Mutations as a Target in AML
AG-221 Preclinical Data
Phase 1 Study of AG-120 in IDH1-Mutant Hematologic Malignancies
Phase 1 Study of AG-221 in IDH2-Mutant Hematologic Malignancies
Results of AG-221 Phase 1 Study
Responses With AG-221
Differentiation Effect in the Bone Marrow
IDH1 (AG-120) and IDH2 (AG-221) Inhibitors: Ongoing and Planned Studies
Abbreviations
Abbreviations (cont)
References
References (cont)
References (cont)
References (cont)
References (cont)
References (cont)